Curriculum vitae

Ashkan Pirmani

Applied machine learning · Real world evidence · Drug safety methods

Health data is scattered. I work on what we can still learn when it has to stay that way.

45.5% more

records in a worldwide study of multiple sclerosis medicines and COVID-19, through the federated route I built. Its findings informed the global advice for people with multiple sclerosis.

JMIR Medical Informatics, 2023

31% higher

AUC-PR from personalizing a federated model to each of 32 countries, on 26,246 patients.

npj Digital Medicine, 2025

24% higher

AUC-PR with FLoRank, my low-rank personalized federated method, over standard federated learning.

ECTRIMS 2025, with an ECTRIMS grant

18

registries agreed on one core data set I designed, with the same quality checks on every stream.

JMIR Medical Informatics, 2023

On this page
  1. At a glance
  2. Experience
  3. Skills, with proof
  4. Worked with
  5. Education
  6. Recognition
  7. Teaching
  8. Publications

Now, since September 2026

Drug safety methods, with Johnson & Johnson Innovative Medicine as industry partner

An Innovation Mandate: a personal grant from the Flemish government's innovation agency (VLAIO). I am building methods that keep two treatment groups comparable when each data source has few patients: first in multiple sclerosis, against criteria set in advance, then on Optum's US health records and insurance claims.

Read the plan

Seven years at a glance

201520162017201820192020202120222023202420252026MBA, quality engineeringMSc, industrial engineeringResearch assistant, IranDocDual PhDPostdoctoral researcherInnovation MandateInnovation Mandatejournal paperabstract, chapter, preprint or thesis

Roles as bars, and every entry in the publications list as a dot in its year.

Experience

2026 to now

Innovation Mandate, drug safety methods

Hasselt University, with Johnson & Johnson Innovative Medicine as industry partner. Belgium.

  • Won a personal Innovation Mandate grant from the Flemish government's innovation agency (VLAIO), with Johnson & Johnson Innovative Medicine as industry partner.
  • Developing methods that keep two treatment groups comparable in propensity score analyses when each data source has few patients: first in multiple sclerosis against criteria set in advance, then on Optum's US health records and insurance claims. The plan.
2024 to 2026

Postdoctoral researcher

KU Leuven, Department of Electrical Engineering, and Hasselt University, Data Science Institute, jointly funded. Belgium.

  • Personalizing a federated model to each of 32 countries improved ROC-AUC by 7.2% and AUC-PR by 31% over the same model without personalization, and beat pooling all records, on 26,246 patients. First author, npj Digital Medicine (2025).
  • FLoRank, my personalized federated method built on adaptive low-rank factorization, improved AUC-PR by 24% over standard federated learning and F1 by 8% over LoRA, on registry data from over 26,000 patients at 146 centers. Prototype. ECTRIMS personal grant for scientific quality (2025).
  • FLkit, an open guide for teams starting studies across centers that keep their own data: 29 contributors, supported by ELIXIR Belgium. I led its design. First author, arXiv (2026).
  • Identified five barriers that stop research software from being reused, from scope to institutional trust, by retiring my own framework, FL4E. First author, Medical Informatics Europe (2026).
  • Organizing team of OHDSI Europe 2025. Invited talks at Roche, the Flower community and the North American Society of Artificial Intelligence in Multiple Sclerosis.
  • Coordinated with data holders, clinicians and legal teams in more than thirty countries. Supervised master's students.
2019 to 2024

Doctoral researcher

KU Leuven and Hasselt University.

  • Added 3,527 records, 45.5% more, to a worldwide study of multiple sclerosis medicines and COVID-19, through a federated route I built for registries that could not send data: a Docker container at each registry turned its records into grouped counts. Its findings informed the global COVID-19 advice for people with multiple sclerosis. First author, JMIR Medical Informatics (2023).
  • Designed the collection's data pipeline: one core data set agreed across 18 registries, three routes for data to come in, and the same quality checks on every stream.
  • In over 5,500 people with multiple sclerosis, the anti-CD20 medicines ocrelizumab and rituximab were associated with more severe COVID-19 than glatiramer acetate, and interferon-β was not protective compared with other medicines. My part was data acquisition, the pipeline and the federated route. Shared first author, Neurology: Neuroimmunology & Neuroinflammation (2022) and Multiple Sclerosis and Related Disorders (2022).
  • Led the disability progression study, from the data access proposal to MSBase and the ethics approval to the experiments. Designed AdaptiveDualBranchNet in Python and PyTorch, and ran it with Flower and Ray on the Flemish Supercomputer Center's cluster.
  • ATHENA, a public-private partnership with Janssen Pharmaceutica, funded part of the PhD. Worked on the analysis in its machine learning work package.
  • Built FL4E, a framework for federated studies, and the degree of federation, tested on classification and on survival analysis. On a public classification benchmark, letting half the centers send their records kept 97.5% of the fully federated score. First author, JMIR Formative Research (2024).
  • Taught in the Data Science in Healthcare course at Hasselt University, and began supervising master's theses in 2021.
2017 to 2019

Research assistant, Decision Support Systems Lab

IranDoc, Iranian Research Institute for Information Science and Technology, Tehran.

  • A simulation of Iran Post's national parcel network in R and NetLogo, searched with a genetic algorithm for a better set of hubs, found a layout with 15% lower projected transport cost, in simulation.
  • Delivered as a decision support dashboard and a policy analysis for senior executives.

Skills, with proof

Methods

  • Federated learning and federated analysis
  • Personalization when sites hold different patients
  • Privacy-preserving machine learning
  • Survival analysis and classification on clinical data

Data

  • Real world and observational data
  • Cohort building and phenotype definition across registries
  • Registry harmonization and data quality
  • Data feasibility: whether a question can be answered at all
  • OMOP common data model, through OHDSI
  • FAIR data practice

Tools

  • Python
  • PyTorch
  • Flower
  • Ray
  • scikit-learn and pandas
  • R
  • SQL
  • Docker
  • Kubernetes and continuous integration

Networks

  • OHDSI Belgium, and the organizing team of OHDSI Europe 2025
  • ELIXIR Belgium
  • The MSBase registry and the MS Data Alliance

Worked with

  • Johnson & Johnson Innovative MedicineIndustry partner of my Innovation Mandate
  • Janssen PharmaceuticaATHENA partnership, which funded part of my PhD
  • RocheInvited talk, to its federated learning team for multiple sclerosis
  • MSBaseRegistry data from 26,246 patients in 32 countries
  • MS International FederationThe worldwide COVID-19 data collection behind its advice
  • OHDSI EuropeOrganizing team of the 2025 symposium
  • ELIXIR BelgiumSupports FLkit
  • Flemish Supercomputer CenterCompute for the federated experiments
  • FlowerInvited talk at Flower Monthly

Education

2019 to 2024

Dual PhD

Electrical engineering, KU Leuven. Biomedical sciences, Hasselt University. Defended November 2024.

  • Thesis: From Centralized to Federated. The Journey of Data in Healthcare.
  • Supervisors: Yves Moreau (KU Leuven), Liesbet M. Peeters (Hasselt University). Co-supervisor: Niels Hellings.
2016 to 2019

MSc, Industrial Engineering

Socio-economic systems. Kharazmi University, Tehran.

2015 to 2017

MBA, Quality Engineering

Tose'e Institute, Tehran.

Recognition

2026

Innovation Mandate

Flanders Innovation and Entrepreneurship, with Johnson & Johnson Innovative Medicine as the industry partner. Drug safety research on health records and insurance claims.

2025

ECTRIMS personal grant for scientific quality

For FLoRank, at ECTRIMS 2025, Barcelona.

2019

Fully funded PhD scholarship

KU Leuven and Hasselt University, through to the defense in 2024.

Teaching and supervision

2022 to 2024

Data Science in Healthcare

Teaching member, Healthcare Engineering program, Hasselt University. Two academic years.

2021 to now

Master's thesis supervision

Seven master's theses in artificial intelligence, KU Leuven.

  • Predicting admission to care. Federated, pooled and local data compared.
  • How splitting the data changes what the model learns.
  • Federated boosting in semi-supervised learning.
  • Contrastive learning for federated models.
  • Personalized models. Architectures and parameter exchange.
  • Fine-tuning a global federated model for local performance.
  • Early disease detection from shallow whole genome sequencing of cell-free DNA.

Selected publications

2026Development and Design of FLKit: A Structured Onboarding Toolkit for Federated Learning in Health and Life SciencesarXiv preprint arXiv:2606.23500. Pirmani, Vermeulen, Vinterhalter, Geys, Faes, Ali, et al. 2026Good for All, Not Good Enough for One: Reuse Dilemma in Federated LearningStudies in Health Technology and Informatics. Pirmani, Moreau, Peeters 2025FLoRank: adaptive structured personalisation for federated prediction of disability progression in multiple sclerosisECTRIMS 2025, Multiple Sclerosis Journal 31(3 suppl). Pirmani, Moreau, Peeters 2025Personalized federated learning for predicting disability progression in multiple sclerosis using real-world routine clinical datanpj Digital Medicine. Pirmani, De Brouwer, Arany, Oldenhof, Passemiers, Faes, et al. 2024Accessible ecosystem for clinical research (federated learning for everyone): development and usability studyJMIR Formative Research. Pirmani, Oldenhof, Peeters, De Brouwer, Moreau 2023The Journey of Data Within a Global Data Sharing Initiative: A Federated 3-Layer Data Analysis Pipeline to Scale Up Multiple Sclerosis ResearchJMIR Medical Informatics. Pirmani, De Brouwer, Geys, Parciak, Moreau, Peeters 2022Severity of COVID19 infection among patients with multiple sclerosis treated with interferon-betaMultiple Sclerosis and Related Disorders. Simpson-Yap, Pirmani, De Brouwer, Peeters, Geys, Parciak, et al. (shared first author) 2022Updated results of the COVID-19 in MS global data sharing initiative: anti-CD20 and other risk factors associated with COVID-19 severityNeurology: Neuroimmunology & Neuroinflammation. Simpson-Yap, Pirmani, Kalincik, De Brouwer, Geys, Parciak, et al. (shared first author) 2021Associations of disease-modifying therapies with COVID-19 severity in multiple sclerosisNeurology. Simpson-Yap, De Brouwer, Kalincik, Rijke, Hillert, Walton, et al.

All 22 entries are on the publications page. Talks, including Roche, Flower, ECTRIMS and Medical Informatics Europe, are on the talks page.

Let's talk.

If your question depends on real world health data, I probably want to hear about it.

Email me

TurkishMerhabaAzeri, my mother tongue, as written in Urmia: xoş gəldin, welcomeخوش گلدینAzerbaijani, as written in AzerbaijanSalamPersian, the language of school: dorudدرودEnglishHelloDutch, as said in FlandersDagyou
A greeting in each language I speak, where it lives.